Spectral Diagnostics (OTCMKTS:EDTXF – Get Free Report) announced its earnings results on Friday. The company reported ($0.01) earnings per share for the quarter, meeting the consensus estimate of ($0.01), Zacks reports. The firm had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $0.42 million.
Spectral Diagnostics Price Performance
Spectral Diagnostics stock opened at $0.68 on Friday. Spectral Diagnostics has a 12-month low of $0.64 and a 12-month high of $1.10. The company has a market capitalization of $201.15 million, a price-to-earnings ratio of -22.76 and a beta of 0.21. The firm’s fifty day moving average price is $0.81 and its 200 day moving average price is $0.94.
About Spectral Diagnostics
Spectral Diagnostics Inc is a Canadian medical technology company focused on improving the diagnosis and treatment of sepsis and septic shock. The company develops products designed to identify endotoxin activity, an important factor in certain severe infections and inflammatory conditions.
Its principal diagnostic product is the Endotoxin Activity Assay, a blood test intended to measure a patient’s level of endotoxin activity and help identify individuals who may be at increased risk of developing severe sepsis.
Featured Stories
- Five stocks we like better than Spectral Diagnostics
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
Receive News & Ratings for Spectral Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
